Sumitomo Dainippon Pharma Oncology Email Format
Pharmaceutical ManufacturingMassachusetts, United States201-500 Employees
Sumitomo Dainippon Pharma Oncology is the U.S.-based oncology subsidiary of Sumitomo Pharma Co., Ltd., dedicated to developing novel cancer therapeutics. The organization coordinates discovery research, external innovation, clinical development and commercialization across its teams in Cambridge, Massachusetts; Lehi, Utah; and in Tokyo and Osaka, Japan. Its Cambridge site at 640 Memorial Drive anchors part of its U.S. operations. The company's pipeline targets oncogenic pathways, survival mechanisms and novel protein interactions to address unmet clinical needs in oncology. Recent activity in 2026 includes SMPA presenting clinical and translational data at the EHA conference on investigational therapy for relapsed/refractory myelofibrosis and on menin inhibition in leukemia.